Bausch Health Appoints Michael Goettler, Sandra Leung to Board of Directors.

Bausch Health Companies Inc. has appointed Michael Goettler and Sandra Leung to its Board of Directors, increasing the size to twelve members. Goettler has extensive leadership experience in the pharmaceutical industry, previously serving as CEO of Viatris. Leung is a seasoned executive with experience in the life sciences and healthcare sectors. Their appointments expand the company's expertise and leadership.

Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) has expanded its Board of Directors to twelve members with the appointment of Michael Goettler and Sandra Leung, effective July 22, 2025 [1]. The appointments aim to enhance the company's strategic guidance and expertise in the pharmaceutical industry.

Michael Goettler, a seasoned executive with extensive leadership experience, previously served as the Chief Executive Officer of Viatris. He will serve on the Talent and Compensation Committee and the Science and Technology Committee [1]. Goettler is recognized for his expertise in steering multinational corporations and advancing healthcare solutions worldwide.

Sandra Leung, who brings decades of experience in the pharmaceutical industry, most recently held the position of Executive Vice President and General Counsel at Bristol Myers Squibb Company. She will join the Nominating and Corporate Governance Committee [1]. Leung's strategic legal counsel has guided corporate governance, compliance, and regulatory initiatives at the highest levels.

John A. Paulson, Chairperson of the Bausch Health Board, expressed confidence that their extensive industry knowledge and leadership capabilities will provide invaluable guidance for the company's continued evolution and strengthen its commitment to stakeholders [1].

Bausch Health Companies Inc. is a global, diversified pharmaceutical company that develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals, and eye health [1]. The company's ambition is to be a globally integrated healthcare company, trusted and valued by patients, healthcare professionals, employees, and investors.

The appointments of Goettler and Leung come with the company's forward-looking statements, which may contain risks and uncertainties that could cause actual results to differ materially from those described in the statements [1].

References:
[1] https://www.morningstar.com/news/accesswire/1052125msn/bausch-health-announces-the-appointment-of-two-new-members-to-its-board-of-directors